Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Cash from Investing Activities of $123.1 million for Q1 2026, up 172.84% year-over-year from $45.1 million in Q1 2025, and up 133.08% quarter-over-quarter from -$372.2 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $123.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 172.84% year-over-year to $123.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 200.48% YoY), while the FY2025 annual figure was -$1.5 billion, down 197.11% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $123.1 million, up from -$372.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $214.1 million in Q3 2024, with the low at -$641.0 million in Q2 2025.
- The 5-year median for Cash from Investing Activities is -$169.0 million (2025), against an average of -$147.3 million.
- Peak annual rise in Cash from Investing Activities reached 222.83% in 2024, while the deepest fall reached 5538.82% in 2024.
- Jazz Pharmaceuticals' Cash from Investing Activities stood at -$324.4 million in 2022, then soared by 131.38% to $101.8 million in 2023, then plunged by 289.87% to -$193.3 million in 2024, then tumbled by 92.54% to -$372.2 million in 2025, then surged by 133.08% to $123.1 million in 2026.
- Business Quant data shows JAZZ's Cash from Investing Activities at $123.1 million in Q1 2026, -$372.2 million in Q4 2025, and -$327.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 354.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 354.90 Mn |
| Jun 30, 2026 | 354.90 Mn |
| Mar 31, 2026 | 123.10 Mn |
| Mar 31, 2026 | 123.10 Mn |
| Dec 31, 2025 | -372.16 Mn |
| Dec 31, 2025 | -372.16 Mn |
| Sep 30, 2025 | -327.80 Mn |
| Sep 30, 2025 | -327.80 Mn |
| Jun 30, 2025 | -640.95 Mn |
| Jun 30, 2025 | -640.95 Mn |
| Mar 31, 2025 | -169.00 Mn |
| Mar 31, 2025 | -169.00 Mn |
| Dec 31, 2024 | -193.29 Mn |
| Dec 31, 2024 | -193.29 Mn |
| Sep 30, 2024 | 214.09 Mn |
| Sep 30, 2024 | 214.09 Mn |
| Jun 30, 2024 | -257.09 Mn |
| Jun 30, 2024 | -257.09 Mn |
| Mar 31, 2024 | -271.90 Mn |
| Mar 31, 2024 | -271.90 Mn |